news

First-of-a-kind EU approval granted for eosinophilic esophagitis medicine

1
SHARES

With its novel approach for addressing a fundamental cause of eosinophilic esophagitis, approval of the biologic marks a potential new standard of care for paediatric patients.

eosinophilic esophagitis Dupixent

Dupixent (dupilumab) has been approved by the European Medicines Agency (EMA) as the first treatment for young children with eosinophilic esophagitis in the EU.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

This authorisation is based on Phase III data which found that 68 percent of children aged one to 11 years given Dupixent (dupilumab) achieved histological disease remission at 16 weeks. This result was maintained for up to one year.

The biologic treatment is indicated for these individuals “who weigh at least 15kg and who are inadequately controlled by, intolerant to, or who are not candidates for conventional medicinal therapy”, according to the EMA.

The agency’s decision expands the initial approval of the treatment in the EU for eosinophilic esophagitis in adults and adolescents. The medicine has been jointly developed by Sanofi and Regeneron.

In the Phase III trial, at 16 weeks, in Part A of the study, children given a higher dose of Dupixent based on a weight-based dosing regimen achieved an 86 percent reduction in peak esophageal intraepithelial eosinophil count, the data showed.

What EU approval of Dupixent means for eosinophilic esophagitis patients

This milestone provides an important new treatment for paediatric patients who were previously without options specifically approved for their disease”

“Up to half of all children in the EU with eosinophilic esophagitis remain uncontrolled despite existing standard of care treatment options… This milestone provides an important new treatment for paediatric patients who were previously without options specifically approved for their disease.

“With this novel approach to addressing an underlying cause of eosinophilic esophagitis, Dupixent has the potential to give these young children a better chance to thrive,” explained Dr Houman Ashrafian, PhD, Executive Vice President, Head of Research and Development, Sanofi.

Findings from this Dupixent eosinophilic esophagitis study were published in The New England Journal of Medicine.

Share via
Share via